This paper is only available as a PDF. To read, Please Download here.
Abstract
The beta-adrenoceptor antagonist propranolol is used in the therapy of hypertension
and ischemic heart disease. The aim of our study was to evaluate the effects of this
drug on platelet aggregation and on synthesis of thromboxane B2 (the stable metabolite of Thromboxane A2) from platelet rich plasma (PRP), whole blood samples and during spontaneous clotting.
The results indicate that propranolol at concentrations near the therapeutic range,
significantly inhibit collagen and thrombin-induced platelet aggregation and TxB2 synthesis from PRP. Furthermore the drug demonstrates inhibitory activity on B-TG
release and TxB2 production from whole blood samples and on spontaneous clotting. The results suggest
that some benefits of propranolol in the treatment of patients with coronary artery
disease or cardiovascular conditions associated with platelet hyperaggregability may
also be related to interference with platelet activation “in vivo” and with TxA2 generation.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Prostaglandins, Leukotrienes and Essential Fatty AcidsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Platelet beta-adrenoceptors.Br J Pharmacol. 1983; 79: 681
- Platelet adrenoceptors.in: Longenecker GL the platelets: Physiology and Pharmacology. Academic Press, Orlando1985: 113
- Calcium and cyclic AMP antagonistic modulators of platelet function.in: Longenecker GL The Platelets: Physiology and Pharmacology. Academic Press, Orlando1985: 237
- Effect of long term beta-blockade with alprenolol on platelet function and fibrinolytic activity in patients with coronary heart disease.Eur J Clin Pharmacol. 1981; 20: 242
- platelet aggregation and beta-blockers.Lancet. 1982; 1: 224
- Effect of metoprolol and propranolol on platelet aggregation and cAMP levels in hypertensive patients.Eur J Clin Pharmacol. 1986; 29: 561
- The effect of various beta-receptor blocking agents on platelet aggregation.Experientia. 1978; 25: 280
- Effect of propranolol on platelet function.Blood. 1977; 49: 185
- Antiplatelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment.Lancet. 1981; 2: 1382
- Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets.Circulation. 1985; 71: 1237
- The in vitro effect of amrinone on thromboxane B2 synthesis in human whole blood.Thromb Res. 1986; 42: 817
- A randomized trial of propranolol in patients with acute myocardial infarction: Mortality results.JAMA. 1982; 247: 1707
- Aggregation of blood platelets by adenosine diphosphate and its reversal.Nature. 1962; 194: 927
- Thrombocytopenia due to abnormalities in platelet release-reaction.Blood. 1972; 39: 2
- Methods in dose response platelet aggregometry.Thrombosis and Haemostasis. 1985; 54: 216
- Epidemiological characteristics of platelet aggregability.Br Med J. 1985; 290: 428
- Statistical methods in medical research.Blackwell, Oxford1971
- Plasma propranolol levels in adults.Clin Pharmacol Ther. 1970; 11: 112
- Local anesthetics, chlorpromazine and propranolol inhibit stimulus-activation of phospholipase A2 in human platelets.Mol Pharmacol. 1978; 16: 171
- Local anesthetics, mepacrine and propranolol are antagonists of calmodulin.in: Proc Natl Acad Sci. 78. 1981: 795
- Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.Haemostasis. 1987; 17: 147
- Pharmacology of platelet-affecting drugs.Circulation. 1980; 62: V-26-V-41
- Formation and regulation of platelet and fibrin haemostatic plug.Human Pathology. 1987; 18: 111
- Platelet lumping produced by connective tissue suspensions and by collagen.in: Proc Soc Exp Biol Med. 109. 1963: 779
- Mechanisms of platelet shape-change, aggregation and release induced by collagen, thrombin and A23187.J Lab Clin Med. 1977; 90: 707
- Platelet activating factor (PAF-Acether) secretion from platelets: effect of aggregating agents.Br J Haematol. 1980; 46: 455
- ADP-dependent common receptor mechanism for binding of Von Wille-brand and fibrinogen to human platelets.in: Proc Natl Acad Sci. 81. 1984: 4935
- Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides.in: Proc Nat Acad Sci. 72. 1975: 2994
- Modulation of human platelet function by prostacyclin and thromboxane A2.in: Fed Proc. 32. 1979: 83
- Thromboxane A2 in vasotonic angina pectoris.N Engl J Med. 1981; 304: 992
- Releasae of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.N Engl J Med. 1981; 304: 685
- Significance of platelet function and Thromboxane B2 levels across the myocardial vascular bed in man.Acta Med Scand. 1981; 210: 111
- Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina.Thromb Res. 1987; 46: 303
- Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium.J Molec Cell Cardiol. 1982; 14: 483
Article info
Identification
Copyright
© 1989 Published by Elsevier Inc.
